

NATURAL KILLER (NK) AND NK-LIKE CELLS AT MUCOSAL EPITHELIA: MEDIATORS OF ANTI-MICROBIAL DEFENSE AND MAINTENANCE OF TISSUE INTEGRITY

A. Fuchs* and M. Colonna

Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, Missouri 63110, USA

Received: October 9, 2011; Accepted: October 11, 2011

Natural killer (NK) cells are innate lymphocytes that play important roles in the defense against microbial pathogens through secretion of IFN- γ and recognition and lysis of virally or bacterially infected host cells. A recently identified population of NK-like cells that shares characteristics of both NK cells and lymphoid tissue inducer (LTi) cells promotes innate immune responses in epithelial tissue through the secretion of IL-22. In contrast to classical NK cells, NK-like cells are localized preferentially at mucosal sites, such as the intestinal mucosa. In this review, we consider the function of NK and NK-like cells in anti-microbial defense as well as the maintenance of tissue integrity in the mucosal epithelium of the intestine, lung, and female reproductive tract. Current experimental evidence supports an important protective role for IL-22-producing NK-like cells during intestinal infections, whereas classical NK cells are crucial in the early defense against many pathogens in the respiratory tract. NK cells isolated from the pregnant uterus differ significantly in phenotype and function from those at other tissue locations. Uterine NK cells clearly contribute to the tissue remodeling that takes place during placentation, but their role in anti-microbial defense remains largely undefined.

Keywords: natural killer cells, NK-22, NCR22, mucosal epithelium, innate immune defense, intestinal epithelium, lung epithelium, uterine NK cells

Natural killer cells

Natural killer (NK) cells play a crucial role in the first line of defense against invading pathogens. The main functions of NK cells include the ability to rapidly secrete cytokines following their recognition of pathogens and following cues from antigen-presenting cells (APC) exposed to pathogen-derived components. NK cells also play a vital surveillance role in the innate immune response to pathogens by their ability to directly kill infected tissue cells.

Several subsets of NK cells have been identified based on their surface phenotype and functionality. In the most general sense, NK cells are classified as either “conventional” NK cells (cNK) or “NK-like” cells. Conventional NK cells are best known for their pro-inflammatory and cytotoxic functions upon recognition of virally infected or malignantly transformed cells. NK-like cells include NK cell receptor-expressing lymphocytes that bear resemblance to lymphoid-tissue inducer cells (LTi). These NK-like cells have little or no cytotoxic capacity and their cytokine secretion pattern has been shown to promote innate immune responses in the epithelium, tissue remodeling and wound healing.

This review will cover the known functions of both conventional NK cells and NK-like cells in the anti-microbial defense of mucosal tissues. We will focus on NK cell-me-

diated immune responses at the mucosal epithelium of the intestine and the lung, and we will briefly consider the known functions of NK cells found in the female reproductive tract.

Phenotype and functions of cNK cells

In the mouse, conventional NK cells are identified by the co-expression of the NK cell receptors NK1.1 (NKR-P1C, CD161) and NKp46, and by their lack of the T cell marker CD3. Human cNK cells are characterized by their expression of the NK cell receptors CD56 and NKp46, and their lack of the T cell marker CD3. cNK cells are found in many lymphoid and non-lymphoid tissues, such as blood, spleen, liver, lymph nodes, and skin. In addition, cNK cells have been described in mucosal-associated lymphoid tissues, such as the human tonsil and mouse Peyer’s patches, as well as in the intestinal and lung mucosa [1, 2].

cNK cells play important functions in the elimination of virally infected and malignantly transformed cells, as evidenced from experiments in mouse models that lack cNK cells, either through antibody-mediated cNK cell depletion or via genetic defects affecting NK cell development or function [3–6]. cNK cells can directly lyse infected and tumor cells through the release of cytotoxic

*Corresponding author: Anja Fuchs; Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO 63104, USA; Phone: +1-314-362-0368; Fax: +1-314-747-0809; E-mail: afuchs@wustl.edu

granules containing granzymes and perforin, which causes apoptosis in the target cell. In addition, cytotoxicity mediated by NK cells can also be triggered through surface receptor interactions between NK cells and their target cells, e.g. through the cNK cell-expressed death receptor ligand TRAIL. Furthermore, cNK cells are an abundant source of cytokines, in particular IFN- γ , which promotes the killing of intracellular pathogens in phagocytes, as well as the skewing of adaptive immune responses toward a Th1 phenotype [4, 7].

In human blood, two major subsets of cNK cells are found based on their expression levels of CD56 and the IgG receptor CD16. The major population of CD56^{dim} CD16⁺ cells has high cytolytic activity and can act as a rapid source of the pro-inflammatory cytokine IFN- γ . Around 10% of peripheral blood NK cells display the CD56^{bright} CD16⁻ phenotype; these cNK cells possess a low cytotoxic potential, but secrete large amounts of cytokines, such as IFN- γ , GM-CSF, and TNF- α upon *in vitro* stimulation with IL-12 and IL-18. The two cNK cell subsets show different tissue localizations, with CD56^{dim} cells found mainly in the blood and spleen, and CD56^{bright} cells predominantly in lymph nodes [8–10].

The direct equivalents of human CD56^{dim} and CD56^{bright} NK cells do not exist in the mouse due to their expression of different sets of surface receptors; however, several cNK cell subsets with different functions have been described in mice. The major three subsets differ in their expression of the surface markers CD11b (integrin α M) and CD27, with CD11b^{hi} CD27^{hi} cells representing mature cNK cells that are found predominantly in the spleen, liver, and lymph node, and displaying high potential for cytokine production and cytotoxicity. In contrast, CD11b^{hi} CD27^{low} cells are present in peripheral organs such as the lung and are more limited in their cytokine secretion and cytotoxic capacities. The third major subset represents immature NK cells with the surface phenotype CD11b^{low} CD27^{hi}. An additional subset of mouse NK cells has recently been identified that resembles human CD56^{bright} NK cells in their production of ample amounts of cytokines. This subset appears to develop in the thymus, localizes predominantly to the lymph nodes, and is characterized by the expression of the IL-7 receptor (CD127). Also, enriched in lymph nodes is a further population of NK cells that in addition to NK1.1 expresses B220 and CD11c, two markers that are absent from the major NK cell subsets. These NK cells are potent producers of IFN- γ , have a high cytotoxic potential, and have been suggested to represent *in vivo* activated NK cells rather than a separate NK cell subset [2, 7, 11].

Development of human and mouse cNK cells from common lymphoid progenitors occurs in several stages, accompanied by the gradual acquisition of NK cell receptors and effector functions [12, 13]. cNK cell maturation is critically dependent on signaling through the IL-2R common gamma chain (γ c) and the cytokine IL-15, as evidenced by mice deficient in either the *Il2rg* or the *Il15* gene, which lack mature peripheral NK cells [12].

Phenotype and functions of IL-22-producing NK-like cells

We and other groups have recently identified a novel subset of NK-like cells that is found at mucosal-associated lymphoid tissues, such as the human tonsils and Peyer's patches [14–18]. This NK-like cell population displays unconventional functions characterized by their low cytotoxic potential and the secretion of large amounts of the cytokine IL-22. IL-22 is a member of the IL-10 cytokine family; however, unlike IL-10, it targets cells outside of the immune system, such as intestinal epithelial cells. IL-22 induces the secretion of anti-microbial peptides from epithelial cells, thereby enhancing immune functions in the epithelium [19, 20]. In addition, IL-22 promotes epithelial cell survival and migration and thus enhances processes critical to wound healing [20–24]. In NK-like cells, IL-22 secretion is triggered by exposure to IL-23, a pro-inflammatory cytokine produced by APC, which have encountered pathogen-derived material [14, 17]. Thus, a model of innate mucosal responses has emerged, in which the recognition of pathogens by APC leads to IL-23 production, triggering rapid secretion of IL-22 by NK-like cells to promote anti-microbial functions at sites of pathogen invasion. This is accompanied by enhanced wound-healing activity leading to the restoration of tissue integrity [25].

Based on their cytokine secretion profile, we have suggested the term NK-22 cells for NK-like cells that produce IL-22. In the mouse, NK-22 cells can be identified as NK1.1⁻ NKp46⁺ cells expressing the IL-7 receptor alpha chain (CD127) and the transcription factor ROR γ t, the latter of which is associated with their ability to produce IL-22 [16–18]. Human NK-22 cells express the NK cell receptors CD56, NKp46, and NKp44 and, as mouse NK-22 cells, stain positive for CD127 and the transcription factor ROR γ t [14, 15]. Interestingly, human peripheral blood cNK cells show increased transcript levels of IL-22 upon *in vitro* stimulation with IL-2 and IL-12 [26]. Although IL-22 production was not examined at the protein level in this study, and blood cNK cells do not express the transcription factor ROR γ t associated with IL-22 production, a potential role for cNK cells as a source of IL-22 cannot be excluded.

The observation that NK-22 cells are not cytotoxic and do not secrete any substantial amounts of IFN- γ has sparked controversies as to whether these cells can be grouped as part of the NK cell lineage. NK-22 cells share several characteristics with another innate lymphoid cell type called lymphoid tissue inducer (LTi) cells. These cells, which play crucial roles in the fetal development of secondary lymphoid tissues such as lymph nodes, are also potent producers of IL-22 upon IL-23 stimulation [27–29]. However, unlike NK-22 cells, fetal LTi, as well as LTi-like cells found in adult tissues, produce not only IL-22 but also IL-17, a cytokine with potent pro-inflammatory functions. The development of both NK-22 cells and LTi cells, but not that of cNK cells, is dependent on ROR γ t and IL-7. In contrast, IL-15-deficient mice, which

lack cNK cells, display normal numbers of LTi-like and NK-22 cells [17, 18, 27, 30]. Due to these shared developmental requirements, it has been proposed that NK-22 cells and LTi cells develop from the same precursor cell, which may be distinct from the precursor that gives rise to conventional NK cells [31–33]. However, there is evidence that NK-22 cells can give rise to cells with typical cNK features *in vitro*, such as IFN- γ secretion, suggesting that NK-22 cells may represent a precursor for cNK cells [33–35].

The elucidation of the lineage relationship of NK-22 cells is currently a subject of intense investigation. For the purpose of this review, we will refer to the group of IL-22-producing NK-like cells as NK-22 cells, although their relationship to the NK cell lineage is unclear at present. In the following sections, we summarize experimental evidence for the potential roles of both cNK cells and NK-22 cells during microbial infections at mucosal epithelia. We will focus on three mucosal tissues, each with similar, but also some distinct, characteristics: intestine, lung, and the female reproductive tract.

The intestinal mucosa

While the stomach and proximal small bowel are relatively sparsely colonized, the human distal small bowel and the large bowel contain a rich microbial flora reaching up to 10^{12} colony-forming units per gram of luminal content [36]. At the apical surface of intestinal epithelia, a thick mucus layer forms a physical barrier to prevent microbial invasion of the underlying epithelium. Beneath the mucus coating, a single layer of epithelial cells forms the second barrier between intestinal lumen and host tissue. These epithelial cells fulfill important functions by creating a physical barrier to pathogens and by responding to invading pathogens with the rapid production of anti-microbial peptides and chemoattractants to recruit immune cells [37, 38]. Intraepithelial lymphocytes (IEL), mainly consisting of $CD8^+$ T cells, but also NK cells, reside within this epithelial layer, and a variety of leukocytes, including B cells, T cells, APC, and NK cells can be found in the underlying lamina propria (Fig. 1) [38–40]. Furthermore, the intestinal mucosa contains organized clusters of lymphoid tissue such as cryptopatches, isolated lymphoid follicles (ILF), and Peyer's patches [29].




Fig. 1. cNK cells and NK-22 cells in the intestinal mucosa. cNK cells are found in the intestinal epithelium and in the underlying lamina propria, while NK-22 cells and LTi-like cells reside in the lamina propria. Exposure of dendritic cells (DC) to pathogens triggers the release of IL-12 and/or IL-23, which induces IL-22 secretion by NK-22 and LTi-like cells and IFN- γ secretion by cNK cells. Helminth infections have been shown to cause IL-13 production by intraepithelial NK cells. DC, dendritic cell; cNK, conventional NK cell; LTi-like, adult equivalent of fetal lymphoid tissue inducer (LTi) cells

Pathogens typically enter the intestine via the ingestion of contaminated food. Infection occurs at varying sites within the alimentary tract depending on the pathogen and typically involves penetration of the epithelial layer, either by direct attachment and infection of epithelial cells, or by exploiting the antigen-sampling mechanisms of the immune system to be shuttled across the epithelium. Innate immune mechanisms play important roles in the rapid response to invading pathogens and in the initiation of appropriate adaptive immunity. As an innate source of cytokines, NK cells contribute to the immune defense of many different pathogens. In the sections below, we summarize some of the known functions of NK cells during gastrointestinal infections.

Roles of NK cells in intestinal anti-microbial immune responses

NK-22 cells

To elucidate the functions of NK-22 cells during microbial infections, mouse models deficient in innate and/or adaptive sources of IL-22 have often been utilized. However, in many cases, it is difficult or even impossible to differentiate between the roles that NK-22 cells and LTi cells play, since these cell types share high similarity in their developmental requirements, cell surface receptor and transcription factor expression and tissue location. When discussing roles of NK-22 cells in immune responses at mucosal tissues, this caveat has to be kept in mind.

Recent reports from our group and others have demonstrated that NK cells, in particular NK-22 cells, contribute to innate defense against the gastrointestinal pathogen *Citrobacter rodentium* [14, 18]. *C. rodentium* is a gram-negative bacterium that induces colitis in mice, its natural host. Protection from *C. rodentium*-induced mortality requires both innate and adaptive immune mechanisms. *Rag*-deficient mice, which lack adaptive immune cells (T cells, B cells), are able to contain infections with *C. rodentium* within the first several weeks of infection. This initial immune response is mediated by the cytokine IL-22, as demonstrated by studies using IL-22-deficient mice [41]. A role for NK-22 cells and LTi cells is inferred from the observation that these cell types accumulate during *C. rodentium* infection and are capable of producing IL-22. Furthermore, a role for NK cells in this bacterial infection was demonstrated by anti-NK1.1 antibody-mediated NK cell depletion in *Rag*-deficient mice, and by the infection of *Rag*^{-/-} *IL2rg*^{-/-} mice, which lack NK cells in addition to adaptive immune cells. In both models, NK cell deficiency caused an accelerated mortality upon *C. rodentium* infection [14, 18]. However, a recent report suggests that LTi, not NK-22 cells, provide the majority of the IL-22 required for early protection from *C. rodentium* [42]. Further studies and additional animal models are therefore required to more definitively elucidate the contributions of NK-22 cells during the host response to *C. rodentium* infection.

IL-22-producing NK cells and NK cell-like cells also appear to play protective roles in inflammatory bowel disease (IBD), a group of conditions characterized by chronic inflammation of the intestinal mucosa. In IBD, the immune system mounts aberrant responses to the intestinal microbial flora, leading to a breach of the epithelial barrier and a strong pro-inflammatory cytokine environment. IL-22-producing NK-like cells have been identified in experimental mouse models of colitis, and mice deficient in IL-22-producing cells (*Rag1*^{-/-} *Il2rg*^{-/-}; or *Il22*^{-/-} *Rag1*^{-/-}) display more severe colitis than *Rag1*^{-/-} mice with intact IL-22 production [43]. Again, the exact contributions of NK cells and NK-22 cells versus LTi cells are still unknown.

In human intestinal tissues, NK cells with NK-22 characteristics are present and are capable of producing IL-22 upon *in vitro* treatment with IL-23 [14]. A recent study classified CD56⁺ NK cells in colonic lamina propria into NKp44⁺NKp46⁻ and NKp44⁻NKp46⁺ subsets [44]. These subsets of NK cells differed in their cytokine production, with the NKp44⁺NKp46⁻ representing the IL-22-producing RORγt⁺ NK-22 population, while the NKp44⁻NKp46⁺ subset produced IFN-γ and likely represents a conventional NK cell subset. Interestingly, in Crohn's disease, an IBD characterized by Th17-mediated inflammation, the frequency of NK-22 cells in colonic lamina propria was decreased, while the frequency of cNK was markedly increased compared to healthy tissue [44]. Furthermore, NKp44⁻NKp46⁺ NK cells from Crohn's disease patients were more potent in producing IFN-γ in response to IL-23 than the same NK cell subset from healthy individuals. A separate study found increased frequencies of IL-17-producing LTi-like cells in intestinal tissues from Crohn's disease patients compared to healthy individuals, which resembled the innate cell type implicated in promoting colitis in mice [45, 46]. The above observations suggest that the different NK-like and LTi-like cell populations may have divergent roles in Crohn's disease, with NK-22 cells potentially bearing beneficial roles, and LTi-like and cNK cell subsets playing pro-inflammatory roles, potentially exacerbating chronic inflammation.

The role of NK-22 cells in the intestinal immune defense to tissue-damaging pathogens other than *C. rodentium* has not been sufficiently studied. In humans, human immunodeficiency virus (HIV) is an important pathogen causing high viral burden in the gut, associated with intestinal pathology [47]. A recent study has explored whether NK-22 cells are present in non-primate intestinal tissue [48]. This study by Reeves et al. identified NK cells exhibiting an NK-22 phenotype in the gut of macaques, which expressed high transcript levels of IL-22 and, in contrast to human NK-22 cells, also produced IL-17. These NK-22 cells showed low cytotoxic potential. Upon infection with simian immunodeficiency virus (SIV), these gut NK-22-like cells were reduced in number and showed altered functions, resulting in a change of cytokine expression toward IFN-γ. Furthermore, these cells gained cytolytic potential,

as evidenced by increased perforin expression and enhanced degranulation [48]. At present, the significance of the altered NK cell functions during SIV infection is unknown, but a loss of IL-17 and IL-22 contributes to the gut pathology seen in SIV infection [49], and NK-22 cell depletion during SIV infection may thus potentially contribute to the loss of gut integrity.

cNK cells

Conventional NK cells are known to contribute to the immune defense against various gastrointestinal pathogens, in particular intracellular bacteria and parasites. For example, during infections with *Toxoplasma gondii*, an intracellular parasite that initially infects the intestinal epithelium and causes tissue pathology, cNK cells are a major source of protective IFN- γ at early times of infection. IFN- γ is crucial for the development of an appropriate cytotoxic T cell response to the pathogen and induces macrophage activation. cNK cells may also contribute to the rapid elimination of infected cells by direct cytotoxicity. In the absence of cNK cells, impaired priming of CD4⁺ and CD8⁺ T cells was observed [50]. Recently, cNK cells have also been identified as a major source of IL-17 during *T. gondii* infection, a cytokine that confers resistance to this pathogen [51]. In contrast to what has been seen for *C. rodentium*, IL-22 has pathogenic roles during *T. gondii* infection, causing destruction of intestinal tissue integrity [52, 53]. A possible pathogenic role for NK-22 cells has not been described. T cells have been shown to be the major source of IL-22 in this experimental infection; thus, NK-22 cells may not contribute significantly to tissue pathology [52].

In a recent study by Tomasello and colleagues, oral infection of mice with *Listeria monocytogenes* led to rapid activation of both small intestinal cNK and NK-22 cells to produce IFN- γ and IL-22, respectively. However, protection from *L. monocytogenes* dissemination was dependent on IFN- γ , not IL-22, suggesting that cNK cells play a predominant role in limiting bacterial spread in this model [54].

In the host response to the gastrointestinal nematode *Trichinella spiralis*, cNK cells may perform surprising protective roles through their promotion of Th2-type responses, rather than their typical production of the Th1-type cytokine IFN- γ . In experimental infections with this helminth parasite, intestinal cNK cells produced IL-13 that contributed to the early immune response characterized by goblet cell hyperplasia and mucus overproduction, which facilitated expulsion of the parasite [55]. Thus, cNK cells are capable of contributing to the innate immune defense by secreting cytokines that either promote Th1-type or Th2-type immune responses, depending on the pathogen encountered. It is currently unclear whether different subsets of cNK provide the different cytokines seen *in vivo*, or whether the interaction of cNK with pathogens and pathogen-exposed APC determines the types of cytokines produced by NK cells.

The lung epithelium

In contrast to the situation in the distal bowel, the lung is not normally colonized by microbes and in the healthy state is almost sterile. Inhaled microbes are typically trapped in the thin mucus layer covering the lung epithelium and are readily cleared by a combination of mucociliary transport and coughing. Lung epithelial cells create a physical barrier against invading pathogens, but they also have direct roles in innate immune defense through the release of anti-microbial peptides [56, 57]. Yet, many pathogens have evolved mechanisms to invade the lung epithelium, necessitating the presence of immune mechanisms that can readily respond to invading microbes. During infection, lung resident lymphocytes, dendritic cells, and macrophages play important roles in limiting pathogen spread and in recruiting neutrophils and other immune cells from the blood to the site of infection [57].

cNK cells represent up to 10% of lung resident lymphocytes and are thought to play important roles as an early source of IFN- γ and other cytokines (Fig. 2). Inflammatory insults in the lung rapidly recruit blood NK cells [2, 58]. NK cells capable of producing IL-22 have recently been identified in mouse lung tissue [59], where they may contribute to tissue integrity and anti-microbial immune responses. Existing evidence for the roles of NK cell subsets in pathogen clearance and maintenance of tissue integrity in the lung is reviewed below.

Roles of NK cells in anti-microbial immune responses in the lung

NK cells can be found as resident lymphocytes within the healthy lung. Lung epithelial cells produce IL-15 and may thus contribute to the survival of NK cells within the lung mucosa. In the steady state, inflammatory mechanisms in the lung are dampened by cytokines produced by alveolar macrophages, such as IL-10 and TGF- β , and NK cells isolated from healthy lungs show an impaired cytotoxic potential. Upon exposure to infection or *in vitro* culture with type I interferons, these NK cells become readily activated and acquire cytotoxic functions [58].

In mouse lungs, tissue-resident NK cells have been described as almost uniformly expressing markers of mature cNK, such as NK1.1, DX5 (CD49b), CD11b, NKG2D, and Ly49 receptor family members [59, 60]. While an NK-22-like cell subset has not been described in lung tissues, there is some evidence that a subset of conventional lung NK cells are capable of producing IL-22 *in vitro* and *in vivo* upon IL-23 stimulation and viral infection, respectively [59].

Microbial infections of the lung lead to a rapid recruitment of NK cells from the blood, as seen, for instance, in lung tissues from humans and mice with acute influenza infection that contain increased numbers of cNK cells [58]. In experimental influenza infections in mice, lung resident NK cells were responsible for IFN- γ production during the first




Fig. 2. NK cell responses in the lung. Under homeostatic conditions, cNK cell functions are suppressed via IL-10 and TGF- β produced by macrophages and DC. During microbial infections, cytokines released by macrophages and DC promote IFN- γ production by cNK cells, which aids in limiting pathogen spread. During infection with influenza virus, cNK cells can directly recognize viral hemagglutinin (HA) expressed on the surface of infected phagocytes, resulting in IFN- γ production and cytotoxicity toward the infected cell. M Φ , macrophage

few days after infection, while by day 4, most IFN- γ was produced by NK cells recruited from the blood [59]. Mice depleted of NK cells by anti-NK1.1 or anti-asialo-GM1 antibody injection show enhanced susceptibility for severe influenza infection [61, 62]. NK cells can recognize viral hemagglutinin (HA) present on influenza virus-infected cells via their NKp46 receptor, and this interaction is thought to trigger cytotoxicity toward infected target cells [63, 64]. In accordance with this, NKp46-deficient mice show enhanced susceptibility to lethal influenza infection [65].

In mouse models of pulmonary bacterial and fungal infections, NK cells were found to play protective roles against several different pathogens, such as *Staphylococcus aureus*, *Legionella pneumophila*, *Pseudomonas aeruginosa*, *Bordetella pertussis*, and the fungal pathogen *Aspergillus fumigatus* [66–72]. In most of these studies, NK cell-derived IFN- γ was identified as critical for the early anti-microbial response and promoted pathogen clearance. The role of NK cells in mycobacterial infection is less clear. *In vitro*, human NK cells recognize and respond to *Mycobacterium tuberculosis*-infected monocytes and macrophages by inducing intracellular bacterial killing or lysis of the infected phagocyte. This response to *M. tuberculosis*

appears to be mediated by NK cell receptor recognition of an unknown, possibly bacterial, ligand binding to NKp44, as well as NKp46 and NKG2D binding to host cell ligands [73–76]. In a recent study, inhibition of bacterial growth in macrophages was *in vitro* partially mediated by IL-22 production, implicating an unexpected role for cNK-derived IL-22 in anti-microbial protection [77]. Animal models of *M. tuberculosis* infection, however, have resulted in controversial results. While NK cell activation and IFN- γ production have been clearly demonstrated during infection, NK cell depletion experiments suggest a redundant or even detrimental role of NK cells during *M. tuberculosis* infection [58].

In summary, lung-resident NK cells play important roles in the early response to many pathogens. Protective effects of NK cells in lung infections are in most cases mediated by cNK through their production of IFN- γ and by their cytotoxicity toward infected host cells. Potential roles for NK-like cells in lung infections have not sufficiently been explored yet, but unlike intestinal NK cells, resident lung NK cells display a fairly homogeneous phenotype typical of cNK cells [59]. Thus, it is conceivable that lung tissue does not harbor NK-22 cells in steady state or during




Fig. 3. Uterine NK cells have unique functions during pregnancy. In the pregnant uterus, NK cells in the decidua contribute to the tissue remodeling that takes place during placentation. uNK cells mediate trophoblast migration through the secretion of cytokines and chemokines, and they promote vascularization through the release of angiogenic factors. The role of uNK cells during microbial infections is still unclear. VEGF, vascular endothelial growth factor; PLGF, placental growth factor

the experimental models tested to date. However, as mentioned before, cNK cells represent a possible source of IL-22 during infection with intracellular pathogens in the lung [59, 77]. IL-22 plays important roles in the protection of mice from mortality caused by the pneumonia-inducing pathogen *Klebsiella pneumoniae*; however, the contribution of innate cell types to IL-22 production in the lung has not been addressed yet [78].

NK cells in the female reproductive tract

NK cells are present in humans and mice in the decidua, the mucosa lining the uterus during pregnancy. In humans, but not mice, NK cells can also be found in the endometrium, the mucosa of the non-pregnant uterus, where they increase in numbers during the later stages of the menstrual cycle [79, 80]. During pregnancy, immune cells residing within the decidua play important roles in the development of the placenta and in the maintenance of tolerance to the developing fetus. In particular, decidual NK cells, which can make up to 70% of decidual lymphocytes, modulate placentation, neovascularization, and trophoblast

invasion through their secretion of cytokines and angiogenic factors (Fig. 3) [79–82].

NK cells found in the human uterus resemble the CD56^{bright} NK cell subset found in peripheral blood, due to their high expression of CD56, their expression of CD94/NKG2A, and lack of CD16. Uterine NK cells (uNK) also display a variety of cell surface receptors not found on blood NK cells, such as CD9, the tetraspanin CD151 and the activation marker CD69. NK cells with similar phenotypes have also been described in the human cervix, ectocervix, and in the fallopian tubes [79, 81, 83].

In contrast to CD56^{bright} cells, but similar to CD56^{dim} blood NK cells, uNK also show abundant intracellular granzyme and perforin expression. Despite this, uNK cells exhibit only low cytotoxicity to classical NK cell targets, which may in part be mediated by a higher expression of inhibitory NK cell receptors by uNK than blood NK cells. uNK cells are a potent source of a variety of cytokines, such as IFN- γ , TNF- α , GM-CSF, and IL-10. Additionally, they secrete IL-8, vascular endothelial growth factor (VEGF), CXCL10, and SDF-1 that play roles in vascularization, tissue remodeling, and trophoblast migration during placental development [80–82].

The presence of immature NK cells with NK-22 characteristics (IL-22 producing, CD56⁺, CD127⁺, RORC⁺) in the human uterus has recently been described. Upon *in vitro* culture, these cells acquire CD94 and increase CD56 expression, suggesting that they are cells of the NK cell lineage [84]. Their function at this site is not clear to date, but these NK-22 cells may represent an NK cell precursor population that differentiates into mature uNK cells in the uterine mucosa. Their production of IL-22 may play functions in enhancing innate immunity and maintaining tissue integrity at this site.

In vivo, cytotoxicity of NK cells in the human pregnant uterus is suppressed through an anti-inflammatory cytokine milieu, as well as through the interaction of the inhibitory NK cell receptors NKG2A and ILT2 with HLA-E and HLA-G, respectively, expressed on trophoblasts [82]. Infections of the uterine epithelia or the fetus may activate uNK cells to acquire cytolytic potential and to secrete pro-inflammatory cytokines. This is evident from *in vitro* experiments with uNK cells, whereby NKp46 ligation led to potent cytotoxicity. Furthermore, ligation of NKp30, as well as cytokine stimulation with IL-12 and IL-15, led to robust IFN- γ and TNF- α production [83, 85, 86].

The contributions of uNK cells in the female reproductive tract to the innate immune defense are unclear at present. The large number of uNK cells in both the pregnant and non-pregnant uterus suggest a potential role of these cells as an innate source of pro-inflammatory cytokines, such as IFN- γ and TNF- α , in response to infection. However, a lack of uNK cells during experimental *L. monocytogenes* infection did not result in increased bacterial burden in the placenta of pregnant mice [87]. A potential role for uNK cells in anti-viral immune responses was recently described, where uNK cells, but not peripheral blood NK cells, were shown to limit HIV-1 replication *in vitro* through their secretion of CXCL12 [88].

Thus, in the uterus, NK cells represent a unique cell population with versatile functions ranging from maintenance of tolerance to the developing fetus in pregnancy, the modulation of tissue remodeling to ensure proper blood exchange between placenta and fetus, and possible functions in anti-microbial defense.

Conclusions

NK cells have traditionally been identified as innate immune cells with cytotoxic capacities toward tumor cells or microbially infected cells. However, it is becoming increasingly clear that NK cells have divergent functions depending on the tissue environment and their differentiation or maturation stage. NK-like cells that secrete IL-22 and lack cytolytic functions may represent either a separate lineage of cells, or may be a precursor to conventional NK cells. Additionally, precursors of cNK cells may, depending on the tissue location, differentiate into either cytolytic or non-cytolytic NK cells as seen in the uterine mucosa.

The mucosal epithelia found in gut, lung, and uterus differ considerably from each other in their tissue architecture and functions, as well as in their different magnitudes of microbial colonization. The intestine has a rich commensal microflora and is thus constantly exposed to pathogen-derived material. In contrast, the lung epithelium is under healthy conditions not exposed to microbial stimuli, while the female reproductive tract exhibits low levels of microbial colonization. Considering these differences, it seems apparent that different mucosal tissues would harbor unique types of resident innate immune effector cells with divergent activation thresholds and different cytokine patterns to respond appropriately to the inflammatory and pathogenic stimuli encountered in these tissues. Fully elucidating the functions of these NK cell subsets will aid our understanding of innate immune defenses and will prove crucial for the development of future effective anti-microbial vaccines and therapeutics.

Acknowledgement

The authors would like to thank Marina Cella for critical reading of this manuscript.

References

1. Gregoire C et al.: The trafficking of natural killer cells. *Immunol Rev* 220, 169–182 (2007)
2. Shi FD, Ljunggren HG, La Cava A, Van Kaer L: Organ-specific features of natural killer cells. *Nat Rev Immunol* 11, 658–671 (2011)
3. Kim S, Iizuka K, Aguila HL, Weissman IL, Yokoyama WM: In vivo natural killer cell activities revealed by natural killer cell-deficient mice. *Proc Natl Acad Sci U S A* 97, 2731–2736 (2000)
4. Lodoen MB, Lanier LL: Natural killer cells as an initial defense against pathogens. *Curr Opin Immunol* 18, 391–398 (2006)
5. Vivier E, Tomasello E, Baratin M, Walzer T, Ugolini S: Functions of natural killer cells. *Nat Immunol* 9, 503–510 (2008)
6. Wallace ME, Smyth MJ: The role of natural killer cells in tumor control-effectors and regulators of adaptive immunity. *Springer Semin Immunopathol* 27, 49–64 (2005)
7. Strowig T, Brilot F, Munz C: Noncytotoxic functions of NK cells: direct pathogen restriction and assistance to adaptive immunity. *J Immunol* 180, 7785–7791 (2008)
8. Ferlazzo G et al.: The abundant NK cells in human secondary lymphoid tissues require activation to express killer cell Ig-like receptors and become cytolytic. *J Immunol* 172, 1455–1462 (2004)
9. Caligiuri MA: Human natural killer cells. *Blood* 112, 461–469 (2008)
10. De Maria A, Bozzano F, Cantoni C, Moretta L: Revisiting human natural killer cell subset function revealed cytolytic CD56(dim)CD16+ NK cells as rapid producers of abundant IFN-gamma on activation. *Proc Natl Acad Sci U S A* 108, 728–732 (2011)
11. Hayakawa Y, Huntington ND, Nutt SL, Smyth MJ: Functional subsets of mouse natural killer cells. *Immunol Rev* 214, 47–55 (2006)

12. Yokoyama WM, Kim S, French AR: The dynamic life of natural killer cells. *Annu Rev Immunol* 22, 405–429 (2004)
13. Freud AG, Caligiuri MA: Human natural killer cell development. *Immunol Rev* 214, 56–72 (2006)
14. Cella M et al.: A human natural killer cell subset provides an innate source of IL-22 for mucosal immunity. *Nature* 457, 722–725 (2009)
15. Cupedo T et al.: Human fetal lymphoid tissue-inducer cells are interleukin 17-producing precursors to RORC+ CD127+ natural killer-like cells. *Nat Immunol* 10, 66–74 (2009)
16. Luci C et al.: Influence of the transcription factor RORgammat on the development of NKp46+ cell populations in gut and skin. *Nat Immunol* 10, 75–82 (2009)
17. Sanos SL et al.: RORgammat and commensal microflora are required for the differentiation of mucosal interleukin 22-producing NKp46+ cells. *Nat Immunol* 10, 83–91 (2009)
18. Satoh-Takayama N et al.: Microbial flora drives interleukin 22 production in intestinal NKp46+ cells that provide innate mucosal immune defense. *Immunity* 29, 958–970 (2008)
19. Ouyang W: Distinct roles of IL-22 in human psoriasis and inflammatory bowel disease. *Cytokine Growth Factor Rev* 21, 435–441 (2010)
20. Wolk K, Witte E, Witte K, Warszawska K, Sabat R: Biology of interleukin-22. *Semin Immunopathol* 32, 17–31 (2010)
21. Aujla SJ, Kolls JK: IL-22: a critical mediator in mucosal host defense. *J Mol Med (Berl)* 87, 451–454 (2009)
22. Zenewicz LA, Flavell RA: IL-22 and inflammation: leukin' through a glass onion. *Eur J Immunol* 38, 3265–3268 (2008)
23. Sonnenberg GF, Fouser LA, Artis D: Border patrol: regulation of immunity, inflammation and tissue homeostasis at barrier surfaces by IL-22. *Nat Immunol* 12, 383–390 (2011)
24. Ouyang W, Rutz S, Crellin NK, Valdez PA, Hymowitz SG: Regulation and functions of the IL-10 family of cytokines in inflammation and disease. *Annu Rev Immunol* 29, 71–109 (2011)
25. Cooper MA, Colonna M, Yokoyama WM: Hidden talents of natural killers: NK cells in innate and adaptive immunity. *EMBO Rep* 10, 1103–1110 (2009)
26. Wolk K, Kunz S, Asadullah K, Sabat R: Cutting edge: immune cells as sources and targets of the IL-10 family members? *J Immunol* 168, 5397–5402 (2002)
27. Spits H, Di Santo JP: The expanding family of innate lymphoid cells: regulators and effectors of immunity and tissue remodeling. *Nat Immunol* 12, 21–27 (2011)
28. Takatori H et al.: Lymphoid tissue inducer-like cells are an innate source of IL-17 and IL-22. *J Exp Med* 206, 35–41 (2009)
29. Ivanov II, Diehl GE, Littman DR: Lymphoid tissue inducer cells in intestinal immunity. *Curr Top Microbiol Immunol* 308, 59–82 (2006)
30. Sanos SL, Vonarbourg C, Mortha A, Diefenbach A: Control of epithelial cell function by interleukin-22-producing RORgammat+ innate lymphoid cells. *Immunology* 132, 453–465 (2011)
31. Crellin NK, Trifari S, Kaplan CD, Cupedo T, Spits H: Human NKp44+IL-22+ cells and LTi-like cells constitute a stable RORC+ lineage distinct from conventional natural killer cells. *J Exp Med* 207, 281–290 (2010)
32. Satoh-Takayama N et al.: IL-7 and IL-15 independently program the differentiation of intestinal CD3-NKp46+ cell subsets from Id2-dependent precursors. *J Exp Med* 207, 273–280 (2010)
33. Vonarbourg C et al.: Regulated expression of nuclear receptor RORgammat confers distinct functional fates to NK cell receptor-expressing RORgammat+ innate lymphocytes. *Immunity* 33, 736–751 (2010)
34. Cella M, Otero K, Colonna M: Expansion of human NK-22 cells with IL-7, IL-2, and IL-1beta reveals intrinsic functional plasticity. *Proc Natl Acad Sci U S A* 107, 10961–10966 (2010)
35. Hughes T et al.: Interleukin-1beta selectively expands and sustains interleukin-22+ immature human natural killer cells in secondary lymphoid tissue. *Immunity* 32, 803–814 (2010)
36. Guarner F: Enteric flora in health and disease. *Digestion* 73 Suppl 1, 5–12 (2006)
37. Maloy KJ, Powrie F: Intestinal homeostasis and its breakdown in inflammatory bowel disease. *Nature* 474, 298–306 (2011)
38. Hooper LV, Macpherson AJ: Immune adaptations that maintain homeostasis with the intestinal microbiota. *Nat Rev Immunol* 10, 159–169 (2010)
39. Kinoshita N et al.: Autocrine IL-15 mediates intestinal epithelial cell death via the activation of neighboring intraepithelial NK cells. *J Immunol* 169, 6187–6192 (2002)
40. Leon F et al.: Human small-intestinal epithelium contains functional natural killer lymphocytes. *Gastroenterology* 125, 345–356 (2003)
41. Zheng Y et al.: Interleukin-22 mediates early host defense against attaching and effacing bacterial pathogens. *Nat Med* 14, 282–289 (2008)
42. Sonnenberg GF, Monticelli LA, Elloso MM, Fouser LA, Artis D: CD4(+) lymphoid tissue-inducer cells promote innate immunity in the gut. *Immunity* 34, 122–134 (2011)
43. Zenewicz LA et al.: Innate and adaptive interleukin-22 protects mice from inflammatory bowel disease. *Immunity* 29, 947–957 (2008)
44. Takayama T et al.: Imbalance of NKp44(+)/NKp46(–) and NKp44(–)/NKp46(+) natural killer cells in the intestinal mucosa of patients with Crohn's disease. *Gastroenterology* 139, 882–892, e1–3 (2010)
45. Geremia A et al.: IL-23-responsive innate lymphoid cells are increased in inflammatory bowel disease. *J Exp Med* 208, 1127–1133 (2011)
46. Buonocore S et al.: Innate lymphoid cells drive interleukin-23-dependent innate intestinal pathology. *Nature* 464, 1371–1375 (2010)
47. Brenchley JM, Douek DC: HIV infection and the gastrointestinal immune system. *Mucosal Immunol* 1, 23–30 (2008)
48. Reeves RK et al.: Gut inflammation and indoleamine deoxygenase inhibit IL-17 production and promote cytotoxic potential in NKp44+ mucosal NK cells during SIV infection. *Blood* 118, 3321–3330 (2011)
49. Raffatelli M et al.: Simian immunodeficiency virus-induced mucosal interleukin-17 deficiency promotes Salmonella dissemination from the gut. *Nat Med* 14, 421–428 (2008)
50. Miller CM, Boulter NR, Ikin RJ, Smith NC: The immunobiology of the innate response to *Toxoplasma gondii*. *Int J Parasitol* 39, 23–39 (2009)
51. Passos ST et al.: IL-6 promotes NK cell production of IL-17 during toxoplasmosis. *J Immunol* 184, 1776–1783 (2010)
52. Munoz M et al.: Interleukin (IL)-23 mediates *Toxoplasma gondii*-induced immunopathology in the gut via matrix metalloproteinase-2 and IL-22 but independent of IL-17. *J Exp Med* 206, 3047–3059 (2009)
53. Wilson MS et al.: Redundant and pathogenic roles for IL-22 in mycobacterial, protozoan, and helminth infections. *J Immunol* 184, 4378–4390 (2010)
54. Reynders A et al.: Identity, regulation and in vivo function of gut NKp46+RORgammat+ and NKp46+RORgammat– lymphoid cells. *Embo J* 30, 2934–2947 (2011)

55. McDermott JR, Humphreys NE, Forman SP, Donaldson DD, Grecnis RK: Intraepithelial NK, cell-derived IL-13 induces intestinal pathology associated with nematode infection. *J Immunol* 175, 3207–3213 (2005)
56. Evans SE, Xu Y, Tuvim MJ, Dickey BF: Inducible innate resistance of lung epithelium to infection. *Annu Rev Physiol* 72, 413–435 (2010)
57. Holt PG, Strickland DH, Wikstrom ME, Jahnsen FL: Regulation of immunological homeostasis in the respiratory tract. *Nat Rev Immunol* 8, 142–152 (2008)
58. Culley FJ: Natural killer cells in infection and inflammation of the lung. *Immunology* 128, 151–163 (2009)
59. Guo H, Topham DJ: Interleukin-22 (IL-22) production by pulmonary Natural Killer cells and the potential role of IL-22 during primary influenza virus infection. *J Virol* 84, 7750–7759 (2010)
60. Junqueira-Kipnis AP et al.: NK cells respond to pulmonary infection with *Mycobacterium tuberculosis*, but play a minimal role in protection. *J Immunol* 171, 6039–6045 (2003)
61. Kos FJ, Engleman EG: Role of natural killer cells in the generation of influenza virus-specific cytotoxic T cells. *Cell Immunol* 173, 1–6 (1996)
62. Stein-Streilein J, Guffee J, Fan W: Locally and systemically derived natural killer cells participate in defense against intranasally inoculated influenza virus. *Reg Immunol* 1, 100–105 (1988)
63. Arnon TI et al.: The mechanisms controlling the recognition of tumor- and virus-infected cells by NKp46. *Blood* 103, 664–672 (2004)
64. Mandelboim O et al.: Recognition of haemagglutinins on virus-infected cells by NKp46 activates lysis by human NK cells. *Nature* 409, 1055–1060 (2001)
65. Gazit R et al.: Lethal influenza infection in the absence of the natural killer cell receptor gene *Ncr1*. *Nat Immunol* 7, 517–523 (2006)
66. Small CL et al.: NK cells play a critical protective role in host defense against acute extracellular *Staphylococcus aureus* bacterial infection in the lung. *J Immunol* 180, 5558–5568 (2008)
67. Sporri R, Joller N, Albers U, Hilbi H, Oxenius A: MyD88-dependent IFN- γ production by NK cells is key for control of *Legionella pneumophila* infection. *J Immunol* 176, 6162–6171 (2006)
68. Borchers MT et al.: The NKG2D-activating receptor mediates pulmonary clearance of *Pseudomonas aeruginosa*. *Infect Immun* 74, 2578–2586 (2006)
69. Wesselkamper SC et al.: NKG2D is critical for NK cell activation in host defense against *Pseudomonas aeruginosa* respiratory infection. *J Immunol* 181, 5481–5489 (2008)
70. Byrne P, McGuiirk P, Todryk S, Mills KH: Depletion of NK cells results in disseminating lethal infection with *Bordetella pertussis* associated with a reduction of antigen-specific Th1 and enhancement of Th2, but not Tr1 cells. *Eur J Immunol* 34, 2579–2588 (2004)
71. Morrison BE, Park SJ, Mooney JM, Mehrad B: Chemokine-mediated recruitment of NK cells is a critical host defense mechanism in invasive aspergillosis. *J Clin Invest* 112, 1862–1870 (2003)
72. Park SJ, Hughes MA, Burdick M, Strieter RM, Mehrad B: Early NK cell-derived IFN- γ is essential to host defense in neutropenic invasive aspergillosis. *J Immunol* 182, 4306–4312 (2009)
73. Garg A et al.: Vimentin expressed on *Mycobacterium tuberculosis*-infected human monocytes is involved in binding to the NKp46 receptor. *J Immunol* 177, 6192–6198 (2006)
74. Vankayalapati R et al.: Role of NK cell-activating receptors and their ligands in the lysis of mononuclear phagocytes infected with an intracellular bacterium. *J Immunol* 175, 4611–4617 (2005)
75. Esin S et al.: Direct binding of human NK cell natural cytotoxicity receptor NKp44 to the surfaces of mycobacteria and other bacteria. *Infect Immun* 76, 1719–1727 (2008)
76. Esin S et al.: Functional characterization of human natural killer cells responding to *Mycobacterium bovis* bacille Calmette-Guerin. *Immunology* 112, 143–152 (2004)
77. Dhiman R et al.: IL-22 produced by human NK cells inhibits growth of *Mycobacterium tuberculosis* by enhancing phagolysosomal fusion. *J Immunol* 183, 6639–6645 (2009)
78. Aujla SJ et al.: IL-22 mediates mucosal host defense against Gram-negative bacterial pneumonia. *Nat Med* 14, 275–281 (2008)
79. Manaster I, Mandelboim O: The unique properties of human NK cells in the uterine mucosa. *Placenta* 29 Suppl A S60–S66 (2008)
80. Zhang J, Chen Z, Smith GN, Croy BA: Natural killer cell-triggered vascular transformation: maternal care before birth? *Cell Mol Immunol* 8, 1–11 (2011)
81. Vacca P, Moretta L, Moretta A, Mingari MC: Origin, phenotype and function of human natural killer cells in pregnancy. *Trends Immunol* (Epub ahead of print) (2011)
82. Moffett-King A: Natural killer cells and pregnancy. *Nat Rev Immunol* 2, 656–663 (2002)
83. Mselle TF et al.: Unique characteristics of NK cells throughout the human female reproductive tract. *Clin Immunol* 124, 69–76 (2007)
84. Male V et al.: Immature NK cells, capable of producing IL-22, are present in human uterine mucosa. *J Immunol* 185, 3913–3918 (2010)
85. El Costa H et al.: Effector functions of human decidual NK cells in healthy early pregnancy are dependent on the specific engagement of natural cytotoxicity receptors. *J Reprod Immunol* 82, 142–147 (2009)
86. Eriksson M, Meadows SK, Wira CR, Sentman CL: Unique phenotype of human uterine NK cells and their regulation by endogenous TGF- β . *J Leukoc Biol* 76, 667–675 (2004)
87. Barber EM, Pollard JW: The uterine NK cell population requires IL-15 but these cells are not required for pregnancy nor the resolution of a *Listeria monocytogenes* infection. *J Immunol* 171, 37–46 (2003)
88. Mselle TF, Howell AL, Ghosh M, Wira CR, Sentman CL: Human uterine natural killer cells but not blood natural killer cells inhibit human immunodeficiency virus type 1 infection by secretion of CXCL12. *J Virol* 83, 11188–11195 (2009)